South San Francisco, United States
AKASA, founded in 2019, is a U.S.-based company leading the way in the use of generative AI to streamline the healthcare revenue cycle. Its innovative approach is rapidly gaining traction among top health systems, evidenced by the national acclaim for its deployment at Cleveland Clinic, marking it as a standout application of GenAI in healthcare finance.
By delivering an average of $3.1M in additional revenue and enhancing quality indicators significantly, AKASA demonstrates a consistent, measurable impact for its clients. The company’s unique edge lies in creating custom Large Language Models (LLMs) for each health system, boosting accuracy and efficiency in critical areas like prior authorization and clinical coding.
Supported by significant investment from reputable firms like Andreessen Horowitz and BOND, AKASA has secured over $200M in funding, including a recent $120M Series C round. With its strategic approach and substantial backing, AKASA is poised to revolutionize the financial complexities in healthcare.
Suki
